Registration Dossier
Registration Dossier
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 215-245-0 | CAS number: 1314-85-8
Endpoint summary
Administrative data
Description of key information
Extrapolated LD50 oral rat between 50 and 300 mg/kg bw/day.
Key value for chemical safety assessment
Acute toxicity: via oral route
Endpoint conclusion
- Endpoint conclusion:
- adverse effect observed
- Quality of whole database:
- Test procedure in accordance with generally accepted scientific standards and described in sufficient details.
Acute toxicity: via inhalation route
Endpoint conclusion
- Endpoint conclusion:
- no study available
Acute toxicity: via dermal route
Endpoint conclusion
- Endpoint conclusion:
- no study available
Additional information
LD50 rat oral route for Tetraphosphorus trisulphide was extrapolated by preliminary study OECD TG 422 and the value was set between 50 and 300 mg/kg bw/day.
According to annex VIII of the REACH Regulation (EC n.1907/2006) testing by the dermal route is appropriate if: (1) inhalation of the substance is unlikely; and (2) skin contact in production and/or use is likely; and (3) the physicochemical and toxicological properties suggest potential for a significant rate of absorption through the skin. For Tetraphosphorus trisulphide inhalation is unlikely due to the low vapour pressure of the substance and skin contact in production or during the use of matches can occur. However, the experimental dermal absorption of P4S3 after 22h of exposure is very low (1.8 %) and it is even lower considering the only use of Tetraphosphorus trisulphide in the matches where P4S3 is applied included into a resin. The experimental dermal absorption of P4S3 containing as 10 % into the resin was 0.4 % after 30 minutes. Based on the dermal absorption evaluation, an acute dermal toxicity study is not necessary.
Testing by inhalation route is not appropriate for this substance because the exposure of human via inhalation is unlikely.
Justification for classification or non-classification
LD50 rat oral route for Tetraphosphorus trisulphide was extrapolated by preliminary study OECD TG 422 and the value was set between 50 and 300 mg/kg bw/day. The classification H301 (acute oral toxicity cat.3) is suggested for the substance according to the CLP Regulation (EC n.1272/2008), even though this substance has an harmonised classification as H302 (acute oral toxicity cat. 4).
There is no concern regarding acute dermal toxicity of Tetraphosphorus trisulphide considering the experimental dermal absorption data obtained testing the solid substance and the resin at 10 %. The inhalation exposure is unlikely due to the low vapour pressure of the substance.
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.
